Executive Summary – Mesenchymal Stem Cells – Advances & Applications

BioInformant, the only market research firm to exclusively serve the stem cell sector, announces the release of its global strategic report, “Mesenchymal Stem Cells – Advances and Applications.” Published November 2015, it presents 250 pages of coverage for the rapidly-evolving mesenchymal stem cell (MSC) industry.

Called the “most innovative market research firm in the world,” BioInformant tracks MSC industry metrics using continuously maintained dashboards combined with systems to trigger alerts when data exhibits unexpected variation.

A unique attribute of BioInformant is that its management team comes from a BioInformatics background – the science of collecting and analyzing complex biological data. BioInformant is the only known research firm to apply these data analysis techniques to the field of market research. This is important, because 2015 saw the first “thaw and use” ink to make MSCs readily available for 3D printing (RoosterBio and CELLINK), a novel manufacturing approach to produce a nearly unlimited supply of MSCs from iPSCs derived from a single donor (Cynata Therapeutics), and the recommendation for approval of a MSC product in Japan (JR-031 developed by Mesoblast’s Japanese partner, JCR Pharmaceuticals Co. Ltd). It is clear that the scope of the MSC industry is expanding and advanced analytics are required.

In addition, the report describes the current status of MSC research, ongoing clinical trials involving MSCs, late stage MSC clinical trials, and possible uses of MSCs in cell therapy. Because MSCs are a sub-segment of the broader cell therapy (CT) and regenerative medicine (RM) markets, it also gives an overview of the regenerative medicine industry and overall cell therapy industry.

The report also explores recent advances in MSC products and technologies, identifies research priorities by market segment, and assesses 35 leading competitors within the MSC marketplace. For pharmaceutical companies, it reveals how advances in MSC research can reveal potential new drug targets, improve methods of drug delivery, and provide personalized treatment strategies.

BioInformant has a Decade of Historical Data and Utilizes Continuously Maintained Dashboards

Founded in 2006 in Washington, DC, BioInformant is distinctively suited to tracking the MSC industry, because it has been following the industry for a decade, providing a robust database of historical data.

Importantly, BioInformant is always innovating. It tracks traditional market metrics, which include trend rate data for MSC clinical trials, scientific publications, grants, patents, product launches, new market entrants, industry acquisitions, collaborations, and more. However, it also tracks recently discovered social analytics, which are metrics derived from social media sites, search engines, online advertising platforms, and more. It is the only known research firm to take this duel-approach to market analysis.

Another unique attribute of BioInformant is that its management team comes from a BioInformatics background – the science of collecting and analyzing complex biological data. BioInformant is the only known research firm to apply these data analysis techniques to the field of market research.

BioInformant research has been cited on prominent news outlets that include the Wall Street Journal, Nature Biotechnology, CBS News, Medical Ethics, the Center for BioNetworking, and more. BioInformant serves notable clients across the stem cell spectrum, with Fortune 500 companies on its client list including GE Healthcare, Pfizer, Goldman Sachs, Beckton Dickinson, and many more.

Opportunities for Commercializing Mesenchymal Stem Cells

Mesenchymal stem cells (MSCs) are multipotent stem cells that can differentiate into a variety of cell types, including osteoblasts, chondrocytes, myocytes, adipocytes, beta-pancreatic islets cells, and potentially, other cell types. MSCs are of intense therapeutic interest, because they represent a population of cells with the potential to treat a range of acute and degenerative diseases. They are advantageous over other stem cells types for a variety of reasons. They avoid the ethical issues that surround embryonic stem cell research, and repeated studies have found MSCs to be immuno-privileged, which make them an advantageous cell type for allogenic transplantation. MSCs also being explored for use in 3D printing applications, because of their unique capacity to form structural tissues.

Because MSCs represent a valuable market segment, stem cell executives and investors must to have a clear understanding of opportunities and threats occurring within the marketplace. As the technology surrounding MSC production has advanced, novel approaches to MSC manufacturing have emerged. As clinical trials investigating MSCs have increased in number, new companies have entered the marketplace to explore clinical applications.

Other emerging threats that could impact the MSC industry include inconsistent or negative clinical findings, competing technologies, and the potential for other stem cell types to provide better efficiency or function. Fluctuating government perspectives on whether the manipulation of stem cells prior to transplantation into humans should be allowed is also a current “hot topic” among regulatory bodies within the U.S. and other regions worldwide, with such legislation affecting the Regenexx® technology and other therapeutic applications involving MSCs.

However, there is also great potential for growth of the MSC market, with more than 30,000 scientific publications published about the cell type, more than 400 clinical trials underway worldwide, and Google Trend data showing MSC searches to be more than twice as common as the next most popular stem cell type.

Therefore, the main objectives of the report are to consider the following:

• Current status of global regenerative medicine (RM) industry in the utilization of stem cells in general and MSCs in particular
• Current status of global cell therapy (CT) industry, the application of cell therapy in various disease indications, and the total number of clinical trials involving the different types of stem cells
• Current status of MSCs in clinical trials, the dominance of MSCs in the ongoing clinical trials involving stem cells, the various applications of MSCs in different disease indications, and the number of clinical trials involving MSCs for different disease types
• The number of companies involved in the development of MSCs, the clinical trials sponsored by major companies, and their ongoing search for MSCs-based cell therapy products
• Analysis of traditional market metrics (grant rates, clinical trial rates, patent rates, scientific publication rates) and new social analytics (metrics from social media sites, search engines, Google Trends, and more)

Key questions answered in the report are: (Regenerative Medicine = RM; Cell Therapy= CT)

• How many companies are currently supporting the regenerative medicine (RM) industry?
• What is the current regional breakdown of RM industry?
• How many RM products have been approved?
• What are the types of diseases are currently being pursued by RM companies?
• What are the major financial events, partnerships and acquisitions in RM sector?
• How do the large pharma companies perceive the value and long-term prospects of RM and cell therapy (CT)?
• What are the major anticipated RM clinical events in 2015-16?
• What are the major therapeutic opportunities for the big pharma in RM and CT?
• How many CT product candidates have reached the Phase III stage and what are they?
• What are the CT product candidates being developed for cardiovascular diseases, central nervous system, wounds, spine and orthopedics, diabetes and autoimmune diseases?
• What are the major commercially available CT products?
• What is the total number of CT clinical trials at the global level?
• What are the major cell types used in CT clinical trials?
• What are the major indications addressed by CT clinical trials?
• What are the major CT clinical trials that have reached Phase III?
• How many CT clinical trials failed in the past year and what are they?
• What are the contributions of MSCs to the cell therapy industry?
• What are the biological properties of MSCs?
• What do MSCs get differentiated into?
• What bioactive molecules do the MSCs secrete?
• What are the immunomodulatory functions of MSCs?
• What are the factors impacting the acquisition of MSCs?
• What are the various sources of MSCs?
• What are the ongoing clinical trials using bone marrow-derived MSCs (BMMSCs) for kidney diseases?
• What are the major clinical trials focusing on diabetes using BMMSCs?
• What are the major clinical trials involving BMMSCs for cardiovascular diseases?
• What are the major clinical trials focusing on liver diseases by BMMSCs?
• What are the brain-related diseases addressed by clinical trials using BMMSCs?
• How many clinical trials are conducted for intestinal diseases using MSCs?
• What are the details of clinical trials conducted for musculoskeletal diseases using MSCs?
• Number of clinical trials using MSCs derived from Wharton’s jelly for various diseases?
• What are the disease indications addressed by umbilical cord blood-derived MSCs (UCBMSCs) in current clinical trials?
• What is the current number of clinical trials using MSCs?
• How many major clinical trials using MSCs have reached the Phase III?
• What are the MSCs-based cell therapy products available in the market?
• What is the current size of the MSC marketplace

The content and metrics contained in this report were compiled using a broad range of sources, including:

• Stem Cell Grant Databases (RePORT Database, CIRM, MRC, Wellcome Trust – UK)
• Stem Cell Patent Databases (United States Patent and Trade Office, World Intellectual Property Organization)
• Stem Cell Clinical Trial Databases (ClinicalTrials.gov, International Clinical Trials Registry Platform, European Union Clinical Trials Register )
• Stem Cell Scientific Publication Databases (PubMed, Highwire Press, Google Scholar)
• Stem Cell Product Launch Announcements (Trade Journals, Google News)
• Stem Cell Industry Events (Google News, Google Alerts)
• Stem Cell Company News (SEC Filings, Investor Publications, Historic Performance)
• Interviews with Stem Cell Industry Leaders and Executives
• SEC Filings and Related Investor Publications
• Social Analytics Tools for Twitter, LinkedIn, Google Search, Google Trends, and More
• BioInformant’s Proprietary Dashboard of MSC Industry Metrics and 10-Year Historical Database

Key findings within this report include:

• Trend rate data for MSC grants, clinical trials, scientific publications, and patents
• Recent advances in MSC research and clinical applications
• Market size determinations, including future projections through 2020
• Deal-making within the MSC marketplace, including key acquisitions and partnerships
• Competitive assessment of the MSC marketplace, by market segment
• Research priorities by market segment
• Top influencers with the MSC marketplace
• Social analytics for the MSC marketplace
• Twitter User Data, Google Trends User Data, Google Adwords Costs, and Hashtag
• Overview of the broader regenerative medicine (RM) and cell therapy (CT) marketplace
• Company profiles for 35 MSC industry leaders

Table of Contents

1. Executive Summary p.12

2. Report Overview p.14
2.1 Target Demographic
2.2 Key Findings
2.3 Statement of the Report
2.4 Purpose
2.4.1 To Survey Recent MSC Advancements
2.4.2 To Provide a Snapshot” of the Global MSC Market
2.4.3 To Assess Opportunities for Commercialization
2.4.4 To Identify Major Market Players and Assess the Competitive Environment
2.4.5 To Identify Existing and Emerging Trends
2.4.6 To Identify Critical Opportunities and Threats within the MSC Market

3. Research Methodology p.21
3.1Input Sources
3.2 Research & Analysis Methodologies
3.3 Criteria for Identiyfing MSC Market Leaders
3.3.1 Size of Company
3.3.2 Type of Product/Services
3.3.2 Degree of Specialization
3.3.4 Patent Positions
3.3.5 Business Reputation
3.3.6 Financial Strength
3.3.7 Partnerships
3.3.8 Certifications

4. Mesenchymal Stem Cell (MSC) Definitions & Nomenclature p.24
4.1.Definition
4.2.Alternative Nomenclature
4.2.1 Mesenchymal Stem Cell
4.2.2 Marrow Stromal Cell (or Mesenchymal Stromal Cell)
4.2.3 Multipotent Stromal Cell
4.2.4 Colony-Forming Unit-fibroblasts

5. Msc Criteria & Characteristics p.27
5.1Discovery
(Figure) Key Dates in the Discovery of Mesenchymal Stem Cells
5.2Physical Assessment
5.3Functional Attributes
5.4. Benefits of MSCs Relative to Other Stem Cells
(Figure) Benefits of MSCs Relative to Other Stem Cells
5.4.1 Well-Characterized
5.4.2 Non-Controversial
5.4.3 Diverse Differentiation Potential
5.4.4 Ease of Growth in Culture
5.4.5 Flexible Propagation
5.4.6 Clinically Relevant Volumes
5.4.7 Role as Regulatory Cells
5.4.8 Delivery of Gene Products
5.4.9 Favorable Immune Status
5.4.10 Commercially Available Research Tools

6.MSC Isolation Sources p.32
6.1 Adult Sources
(Table) Adult Sources for Mesenchymal Stem Cell (MSC) Isolation
6.2 Fetal Sources
(Table) Fetal Sources for Mesenchymal Stem Cell (MSC) Isolation

7.Commercial Interest IN MSCs p.36
(Table) Differentiation Capacity of Mesenchymal Stem Cells
7.1 Cell Types Derived from MSCs
7.2 Therapeutic Potential of MSCs

8. Introduction To Regenerative Medicine (RM) Industry p.38
8.1 Regenerative Medicine (RM) and Advanced Therapies Industry: A Brief Overview
8.2 Global Breakdown of Regenerative Medicine (RM) Industry by Region
(Table) Global Breakdown of RM Companies by Region
(Figure) Global Breakdown of RM Companies by Region
8.3 Breakdown of Global RM Companies by Type
(Table) Global Breakdown of RM Companies by Type
8.4 Number of RM Clinical Trials by Phase of Development
(Table) Number of RM Clinical Trials by Phase
8.5 Major Financial Events in the RM Industry
(Table) Major Financial Events in RM Industry in 2014
(Figure) Major Financial Events in RM Industry in 2014
8.6 Major Partnerships and Acquisitions in RM Industry
(Table) Major Partnerships and Acquisitions in RM Industry in 2014
(Figure) Major Partnerships and Acquisitions in RM Industry in 2014
8.7 Major Regulatory Milestones in RM Industry
(Table)Major Regulatory Milestones in RM Industry in 2014
(Figure)Major Regulatory Milestones in RM Industry in 2014
8.8 Major Pharma and Biotech Companies Active in Advanced Therapies
(Table) Major Pharma and Biotech Companies Active in Advanced Therapies
(Table) Areas of Focus Among Large Pharmaceutical and Biotech Companies Involved with Advanced Therapies
8.9 Major Corporate Partnerships in RM Industry
(Table) Major Corporate Partnerships in RM Industry in 2014
8.10 Anticipated Major RM Clinical Events
(Table) Anticipated Major RM Clinical Events in 2015

9. Introduction To The Stem Cell Therapy Industry p.54
9.1 Types of Stem Cells Used in Cell Therapy
9.1.1 Human Embryonic Stem Cells
9.1.2 Induced Pluripotent Stem Cells
9.1.3 Mesenchymal Stem Cells (MSCs)
9.1.4 Hematopoietic Stem Cells
9.1.5 Adipose Stem Cells (ASCs)
9.1.6 Neural Stem Cells (NSCs)
(Table)Different Types of Stem Cells Used in Cell Therapy and their Characteristics
9.2 Types of Stem Cells Used in Cell Therapy, by Differentiation Potential
(Figure) Five Types of Stem Cells, by Differentiation Potential
9.2.1Totipotent (or Omnipotent) Stem Cells
9.2.2 Pluripotent Stem Cells
9.2.3Multipotent Stem Cells
9.2.4 Oligopotent stem cells
9.2.5 Unipotent Stem Cells

10.Cell Therapy (CT) Products:Successes And Failures p.60
10.1 Cell Therapy Product Candidates in Late-Stage Clinical Development
(Table) Mesenchymal Stem Cell Product Candidates in Late-Stage Clinical Development
10.2 Cell Therapy Products Being Developed for Cardiovascular Indication
10.3 Cell Therapy Products Being Developed for Other Indications
10.4Major Commercially Available Cell Therapy Products
10.5 Cell Therapy Products Approved in South Korea
(Table 13) Cell Therapy Products Approved in South Korea
10.6Major Cell Therapies in Phase III
10.6.1 Prochymal
10.6.2 Mesenchymal Precursor Cell (MPC)
10.6.3 MyoCell
10.6.4 Ixmyelocel-T
10.6.5 ELAD
10.6.6 HP802
10.6.7 StemEx (Carlecortemcel-L)
10.6.8 LaViv
10.6.9 GSK 2696273
10.6.10 Renew
10.6.11 NT-501 (Renexus)
10.6.12 Neocart
10.6.13 DeNovo ET
10.6.14 MACI
10.7 Clinical Trial Failures in Cell Therapy
10.7.1 Failure of Phase II for MultiStem
10.7.2 Failure of Cardio 133 Trial
10.7.3 Termination of AlloCure’s ACT-AKI Trial
10.7.4 Failed Stroke Trial in India
10.7.5 Failure of HeartiCellGram-AMI Trial
10.7.6 Failure of Adipose MSCs in ARDS
10.7.7 CD133+ in CLI Not Feasible
10.7.8 Failed MSC Trial for Multiple Sclerosis
10.7.9 Failure of Chinese Diabetes Trial
10.7.10Failed Efficacy Trial in AMI by Stempeucel
10.7.11Involvement of Multinational Companies (MNCs) in Cell Therapy Sector
(Table) Major Companies and Products in Development within Cell Therapy Sector

11. The Market For Mesenchymal Stem Cell Therapies p.74
11.1 Market Potential – All Stem Cell Types
11.2.Market Potential – Mesenchymal Stem Cells
11.3 Global Market for Stem Cells by Disease Indication
(Table) Global Market for Stem Cell Therapies by Disease Indication, Through 2021
(Figure) Global Market for Stem Cell Therapies by Disease Indication, Through 2021

12. Research And Therapeutic Applications Of MSCs p.78
(Table) Mesenchymal Stem Cell Research Applications
12.1 Basic Research Applications
12.1.1 MSC Morphology
12.1.2 MSC Detection
12.1.3 Differentiation Capacity
12.1.4 Immuno-modulatory Effects
12.2 Cell Transplantation for Site-Specific Repair
12.2.1 Osteochondral Repair
12.2.2 Myogenic and Myocardial Repair
12.2.3 Neural Repair
12.2.4Pancreatic Repair
12.3 Directed Differentiation of Mesenchymal Stem Cells
12.3.1Directed Differentiation of MSCs into Intra-Mesenchymal Lineages
12.3.2 Directed Differentiation of MSCs into Extra-Mesenchymal Lineages
12.4 Drug Delivery Applications:Engineered MSCs as Carriers of Anti-Cancer Drugs
12.5 Drug Screening
12.6 Gene Transfer Studies
12.7 MSC-Mediated Inhibition of Immune Effector Cells
12.8 Supporting Hematopoietic Cell Applications
12.9 Use of 3-D Scaffolds for Tissue Engineering
12.10 Topical Therapy and Use of MSCs in Wound Healing

13. MSC Product Development Variables – Attributes & Acquisition ..p.94
13.1 Biological Properties of MSCs Contributing to Therapeutic Effects
13.1.1 MSCs’ Capacity to Migrate and Engraft
13.1.2 MSCs’ Differentiation Potential
(Table) Origin and Cell Types Derived from MSCs
13.1.3 MSCs’ Potential to Secrete Multiple Bioactive Molecules
(Table) Important Bioactive Molecules Secreted by MSCs and Their Functions
13.1.4 MSCs’ Potential for Immunomodulatory Functions
(Table) Immunomodulatory Effects of MSCs on Immune Cells
13.1.5 Variable Immunophenotype of MSCs
(Table) Cell Surface Antigen Expressions of MSCs Isolated from Different Sources
13.2 Factors Impacting MSCs Acquisition
13.3 Major Clinical Sources of MSCs
(Table) Major Clinical Sources of MSCs

14. Clinical Applications Of Mesenchymal Stem Cells p.100
14.1 Bone Marrow-Derived Mesenchymal Stem Cells (BMMSCs)
14.1.1 BMMSCs and Kidney
(Table) A Sample of Clinical Trials using BMMSCs for Kidney Diseases
14.1.2 BMMSCs and Pancreas
(Table) A Sample of Clinical Trials Using BMMSCs for Diabetes
14.1.3 BMMSCs and Heart
(Table) A Sample of Clinical Trials Using BMMSCs for Heart Disease
14.1.4 BMMSCs and Liver
(Table) A Sample of Clinical Trials Using BMMSCs for Liver Diseases
14.1.5 BMMSCs and Brain
(Table) Clinical and Experimental Therapies Using MSCs for Neural Diseases
14.1.6 BMMSCs and Intestine
(Table) A Sample of Clinical Trials Using BMMSCs for Intestinal Diseases
14.1.7 BMMSCs and Bone
(Table) A Sample of Clinical Trials Using BMMSCs for Musculoskeletal Diseases
14.2 Adipose-Derived Mesenchymal Stem Cells (ADSCs)
14.2.1 Clinical Appplicationsof Adipose-Derived Mesenchymal Stem Cells (ADSCs)
(Table) ADSCs Transplantation in Clinical Trials by Region/Country in Phase III
14.2.2 Selected ADSC Secretomes and their Functions
(Table) Selected ADSC Secretomes and their Functions
14.3 Mesenchymal Stem Cells (MSCs) Derived from Wharton’s Jelly
14.3.1 Clinical Application Properties of WJ-MSCs
14.3.2 Immunoprivileged Status of WJ-MSCs
14.3.3 Clinical Applications of WJ-MSCs
(Table) A Summary of Clinical Trials Using WJ-MSCs
14.4 Umbilical Cord Blood-Derived MSCs (UCBMSCs)
(Table) Clinical Trials Using UCBMSCs and Targeted Diseases
14.5 Dominance of MSCs in Cell Therapy Clinical Trials

15.Major Diseases Addressed By Mscs In Current Clinical Trials p.112
(Table) Clinical Trials Using MSCs by Disease Type, 2014
(Figure) Clinical Trials Using MSCs by Disease Type, 2014
15.1 MSCs for Treating Liver Diseases
(Table) A Sample of Clinical Trials Using MSCs for Liver Disorders
15.2 MSCs for Neurodegenerative Diseases
(Table): A Sample of Clinical Trials Using MSCs for Neurodegenerative Diseases
15.3 Clinical Trials Using MSCs for Autoimmune Diseases
(Table) A Sample of Phase I and II Clinical Trials for Autoimmune Diseases as of 2012
15.4 Clinical Trials Using MSCs for Diabetes
(Table) A Sample of Clinical Trials Using MSCs for Diabetes
15.5 MSCs for Cardiovascular Repair
(Table) A Sample of Clinical Trials Using MSCs for Cardiovascular Diseases
15.6 MSCs for Musculoskeletal Diseases
(Table) Clinical Trials Involving MSCs for Bone and Cartilage Repair
15.6.1 Studies Using MSCs for Musculoskeletal Indications by Leading Countries
(Table) Studies Using MSCs for Musculoskeletal Indications by Country
15.6.2 Application of MSCs in Joint Diseases
(Table) A Sample of Current Clinical Trials Using MSCs for Osteoarthritis
(Table) A Sample of Clinical Trials Involving MSCs for Bone and Cartilage Repair
15.7 MSCs in Neuron/Spinal Cord Diseases
(Table) Sample of Clinical Trials in Different Countries Using MSCs for Neuron and Spinal Cord Diseases
15.8 MSC Infusion for GvHD
(Table) Clinical Experience of MSCs in GvHD Treatment
15.9 MSCs for Crohn’s Disease
(Table) A Sample of Clinical Trials Using MSCs for Crohn’s Disease
15.10 MSCs in Wound Healing
(Table) Clinical Studies using MSCs for Wound Healing
15.11 Increasing Focus on Immunological Properties of MSCs
(Table) Number of MSC Scientific Publications about Immune/Inflammation by Year
(Figure) Number of MSC Scientific Publications about Immune/Inflammation by Year
15.12 Selected MSCs Late-Stage Pipeline Cell Therapies
(Table) Selected MSCs Late-Stage Pipeline Cell Therapies

16.Market Opportunities For Biobanking Of Mesenchymal Stem Cells p.128
16.1 Types of Mesenchymal Stem Cell Biobanking
(Table) Types of Mesenchymal Stem Cell Biobanking
16.2 Dental Stem Cell Banking (MSC Biobanking)
(Table) Companies Offering Dental Stem Cell Storage (Diversified Cord Blood Banks and Specialty Companies)
16.3 Umbilical Cord Tissue (MSC Biobanking)
16.3.1Definitions
16.3.2Cord Tissue Market Overview
16.3.3Comparison of Cord Blood & Cord Tissue Storage
(Figure) Comparison of Umbilical Cord Blood vs. Umbilical Cord Tissue
16.3.4Clinical Trials Investigating Cord Tissue Derived Mesenchymal Stem Cells (CT-MSCs)
(Table) Medical Conditions Being Investigated for Potential to be Treated with Cord Tissue Derived Mesenchymal Stem Cells (CT-MSCs)
16.3.5 Market Penetration of Cord Tissue within the U.S.
(Table)U.S. Cord Blood Banks Offering Cord Tissue Storage in 2013
(Table)U.S. Cord Blood Banks Offering Cord Tissue Storage in 2015
16.3.6.Pricing of Cord Tissue Storage (Global Analysis)
(Table) Pricing Structures for Cord Tissue Storage
16.4Adipose-Derived MSCStorage
(Table) Companies Offering Adipose-Derived MSC Storage (Both Diversified Cord Blood Banks and Specialty Companies)
16.5 Other Types of MSCBio-Banking:Placental Tissue, Menstrual Stem Cells, Peripheral Blood Stem Cells, Bone Marrow Stem Cells, and More

17.Key Market Metrics For MSCs p.141
17.1Global Breakdown of Mesenchymal Stem Cell Clinical Trials
17.1.1 Breakdown of MSC Clinical Trials, By Phase
Figure: Percentage of Mesenchymal Stem Cell (MSC) Clinical Trials by Phase
17.1.2 Additional Resources
17.1.2 Breakdown of MSC Clinical Trials, By Geography
(Figure) Geographical Assessment of MSC Clinical Trial Activity
(Table) Geographical Breakdown of MSC Clinical Trial Activity
17.1.3 Types of Sponsoring/Collaborating Organizations Supporting MSC Clinical Trials
(Table) Breakdown of MSC Clnical Trial Activity by Sponsoring/Collaborating Organization
(Figure) Breakdown of MSC Clinical Trial Activity by Sponsor/Collaborating Organization
17.1.4 Specific Industry Participants Supporting MSC Clinical Trial Activity
(Table) Industry Participants Sponsoring/Collaborating on MSC Clinical Trials
(Table)Top Industry Participants Sponsoring/Collaborating on MSC Clinical Trials
(Figure) Top Industry Participants Sponsoring/Collaborating on MSC Clinical Trials
17.1.5.Summary of Findings for Mesenchymal Stem Cell Clinical Trials
17.2 Patent Analysis
17.2.1Role of Patent Analysis for Competitive Intelligence
17.2.2 MSC Patent Landscape
17.2.3Methodology of MSC Patent Analysis
17.2.3 MSC Patents Filed in 2015
(Table)Mesenchymal Stem Cell Patents Filed in 2015
17.3 Scientific Publication Analysis
(Table)Analysis of MSC Scientific Publications per Year
(Figure) Analysis of MSC Scientific Publications per Year
(Figure) 5-Year Projections for MSC Scientific Publication Rates (2016-2020)
17.4 Grant Rate Analysis
17.4.1All-Time Analysis of MSC Grants (1997 to Present)
(Table) Number of MSC Grant Rates, by Year (RePORTer Analysis)
17.4.1.1Year-over-Year Trends in MSC Grants
(Table) Number of MSC Projects Funded by NIH Support by Year
(Table) Amount of Funding for MSC Projects Supported by NIH by Year
17.4.1.2Geographical Assessment of MSC Grants
(Table) Geographical Assessment of MSC Grants Funded by NIH Support
17.4.1.3Assessment of MSC Grants By Subject Matter (1997 to Present)
(GRAPH) Breakdown of MSC Grants Funded by NIH Suppport by Subject Matter
17.4.1.4Dominant Principal Investigators
(Table) Leading Principal Investigators for MSC Research
17.4.2 2015 Analysis of MSC Grants
17.4.2.1List of MSC Grants Funded by NIH-Support in 2015 Fiscal Year
(Table)MSC Grants Funded by NIH-Support in 2015 Fiscal Year
17.4.2.2Assessment of MSC Grants by Subject Matter (2015)
(Table) Breakdown of MSC Grants Funded by NIH-Support by Subject

18. Social Analytics For Mesenchymal Stem Cells p.169
18.1Marketing Cost Analysis: Search Term “Mesenchymal Stem Cell”
18.1.1 Pay-Per-Click Cost for the Search Term “Mesenchymal Stem Cell”
(Figure) Google Adwords Price-Per-Click for Term “Mesenchymal Stem Cells” (Plural Search Term; U.S. Only)
(Figure) Google Adwords Price-Per-Click for Term “Mesenchymal Stem Cell” (Singular Search Term; U.S. Only)
(Figure) Google Adwords Price-Per-Click for Term “Mesenchymal Stem Cells” (Plural Search Term; Geography: Worldwide)
(Figure) Google Adwords Price-Per-Click for Term “Mesenchymal Stem Cell” (Singular Search Term; Geography: Worldwide)
(Table) Google Adwords Pay-Per-Click (PPC) Costs for MSCs
18.1.2 Analysis of Derivative Search Terms
(Figure) Search Terms Containing or Relating to the Phrase “Mesenchymal Stem Cell” (Geography: USA Only)
(Figure) Search Terms Containing or Relating to the Phrase “Mesenchymal Stem Cell” (Geography: Worldwide)
18.2 MSC Articles Receiving Most Social Media Shares over Past 12 Months
18.2.1MSC Specific Analysis
(Table) Most Shared MSC Articles of the Past 12 Months
18.2.1Stem Cell Analysis (All Types)
(Table) Most Shared Stem Cell Articles of the Past 12 Months (All Stem Cell Types)
18.3 Google Trend Data for MSCs
18.3.1Google Trend Data - Mesenchymal Stem Cells Only
(Figure)Comparison of Google Trend Data for “Mesenchymal Stem Cells” (Plural) vs. “Mesenchymal Stem Cell” (Singular) over a 10-Year History
(Figure) Google Trend Data for “Mesenchymal Stem Cells” over a 5-Year History
(Figure) Google Trend Data Showing Regional Interest in “Mesenchymal Stem Cells” over a 5-Year History
(GRAPH) Google Trend Data Showing City-by-City Interest in “Mesenchymal Stem Cells” over a 5-Year History
(Table) Google Trend Data Showing Related Searches for “Mesenchymal Stem Cells” over a 5-Year History
(Figure) Groundbreaking Years in Hematopoietic Stem Cell Transplant History
19.3.2Google Trend Data -All Types of Stem Cells
(Figure) Google Trend Data for “Stem Cells” over a 10-Year History
(Figure) Google Trend Data – Comparison of All Types of Stem Cells over a 5-Year History
(Figure) Google Trend Data Showing Regional Interest in “Stem Cells” over a 5-Year History
(Figure) Google Trend Data Showing City-by-City Interest in “Stem Cells” over a 5-Year History
(Table) Google Trend Data Showing Related Searches for “Stem Cells” over a 5-Year History
18.4Twitter Hashtag Data
(Table) Rates of Twitter Usage by Country
18.4.1 Twitter Hashtag Data – Mesechymal Specific Data
(Figure) Top 10 Hashtags Related to “#Mesenchymal” on Twitter
(Table) Top 10 Hashtags Related to “#Mesenchymal” on Twitter
18.4.2 Twitter Hashtag Data – Stem Cells (All Types)
(Figure) Top 10 Hashtags Related to “#StemCells” on Twitter
(Table) Top 10 Hashtags Related to “#StemCells” on Twitter
18.4.3Top Five MSC Influencers on Twitter
(Table) Top 5 MSC Influencers on Twitter
18.4.4 Top Five Stem Cell Influencers on Twitter
(Table) Top Five Stem Cell Influencers on Twitter

19. Selected Company Profiles p.195
19.1 American Type Culture Collection Inc. (ATCC)
19.2 Anterogen Co., Ltd.
19.2.1 Cupistem Injection
19.2.2 Queencell
19.3 Apceth GmbH & Co. KG
19.3.1 Apceth’s Research Areas
19.4 BioCardia Inc.
(Table) BioCardia’s Product Pipeline Overview
19.5 BioRestorative Therapies Inc.
19.5.1 brtxDISC
19.5.2 ThermoStem
19.6 Bone Therapeutics SA
19.6.1 PREOB
19.6.2 ALLOB
(Table) Bone Therapeutics’ Product Pipeline
19.7 BrainStorm Cell Therapeutics Inc.
19.7.1 NurOwn
19.8 CellGenix Technologie Transfer GmbH
19.9 Celprogen Inc.
19.10 CellTherapies P/L
19.10.1Services
19.10.2Product
19.11 Cesca Therapeutics Inc.
19.11.1Surgwerks
19.11.2Cellwerks
19.11.3AutoXress (AXP)
19.11.4MarrowXpress (MXP)
19.11.5Res-Q BMC
19.12 Cyagen Biosciences Inc.
19.12.1 Mesenchymal Stem Cells from Cyagen
(Table) Cyagen’s Mesenchymal Cells
19.12.2 Adipose-Derived Mesenchymal Stem Cells from Cyagen
(Table) Cyagen’s Adipose-Derived MSCs
19.12.3 Mesenchymal Stem Cells with GFP from Cyagen
(Table) Gyagen’s MSCs with GFP
19.12.4Adipose-Derived Mesenchymal Cells with GFP from Cyagen
(Table) Adipose-Derived Mesenchymal Cells with GFP
19.12.5Stem Cell Culture Media from Cyagen
(Table) Cyagen’s Stem Cell Culture Media
19.12.6 Stem Cell Differentiation Media from Cyagen
(Table) Cyagen’s Stem Cell Differentiation Media
19.12.7 Primary Cells from Cyagen
(Table) Primary Cells from Cyagen
19.12.8 Cyagen’s Cryopreservation Media
(Table) Cyagen’s Cryopreservation Media
19.12.9 Cyagen’s Primary Cell Culture Media
(Table) Cyagen’s Primary Cell Culture Media
19.12.10 General Cell Culture Supplements and Specialty Reagents from Cyagen
(Table) General Cell Culture Supplements and Specialty Reagents from Cyagen
19.13 Cynata Therapeutics Ltd.
19.13.1 Cymerus Platform Technology
19.14 Cytori Therapeutics Inc.
19.14.1 Clinical Trial for Scleroderma
19.14.2 Clinical Trials for Osteoarthritis
19.15 Escape Therapeutics
(Table) Escape Therapeutics’ Pipeline Products
19.16 Genlantis
19.17 Kite Pharma Inc.
19.17.1 Engineered Autologous Cell Therapy (eACT)
19.17.2 DC-Ad GM-CAIX
(Table) Kite Pharma’s Pipeline and Clinical Trials
19.18 Life Technologies Corporation
19.19 Lonza Group Ltd.
19.19.1 Selected Products
19.20 Medipost Co. Ltd.
19.20.1 Cartistem
19.20.2 Neurostem
19.20.3 Pneumostem
19.21 Mesoblast Ltd.
19.21.1 Mesoblast’s Product Pipeline Overview
(Table) Mesoblast’s Product Pipeline Overview
19.22 NuVasive Inc.
19.22.1 Osteocel
19.23 Ocata Therapeutics Inc.
(Table) Ocata’s Pipeline of Therapeutic Programs
19.24 Organogenesis Inc.
19.24.1 Apligraf
19.24.2 Dermagraft
19.25Orthofix International N.V.
19.25.1 Trinity Elite
19.25.2 Trinity Evolution
19.26Osiris Therapeutics Inc.
19.26.1 Grafix
19.26.2 OvationOS
19.26.3 Cartiform
19.27 Pluristem Therapeutics Inc.
19.27.1 PLX Cells
19.28 PromoCell
19.29 Regeneus Ltd.
19.29.1 Products
(Table) Regeneus’ Product Pipeline
19.30 ScienCell Research Laboratories
19.31 STEMCELL Technologies Inc.
19.32 Stemedica Cell Technologies Inc.
19.32.1 Stemedyne MSC
19.32.2 Stemedyne NSC
19.32.3 Stemedyne RPE
19.33Stempeutics Research Pvt. Ltd.
19.33.1 Stempeucel
19.33.2 Stempeutron
19.33.3 Stempeucare
(Table) Stempeucel in Clinical Trials by Indication
19.34 TiGenix N.V.
19.34.1 Cx601
19.34.2 Cx611
19.34.3 Cx621
19.35 Vericel Corporation
(Table) Vericel Corporation’s Product Portfolio
(Table) Summary Table for the Companies and Their Product Types